

# 1 **Systematic Reconstruction of Autism Biology with Multi-Level** 2 **Whole Exome Analysis**

3

4 Weijun Luo<sup>1,2\*</sup>, Chaolin Zhang<sup>3</sup>, Cory R. Brouwer<sup>1,2</sup>

5 <sup>1</sup>Department of Bioinformatics and Genomics, UNC Charlotte, Charlotte, NC 28223

6 <sup>2</sup>UNC Charlotte Bioinformatics Service Division, North Carolina Research Campus,  
7 Kannapolis, NC 28081

8 <sup>3</sup>Department of Systems Biology, Department of Biochemistry and Molecular  
9 Biophysics, Center for Motor Neuron Biology and Disease, Columbia University, New  
10 York, New York 10032, USA

11 \*Correspondence: Weijun.Luo@uncc.edu

12

13

## 14 **Abstract**

15 Whole exome/genome studies on autism spectrum disorder (ASD) identified thousands of  
16 variants, yet not a coherent and systematic disease mechanism. We conduct novel  
17 integrated analyses across multiple levels on ASD exomes. These mutations do not recur  
18 or replicate at variant level, but significantly and increasingly so at gene and pathway  
19 level. Genetic association reveals a novel gene+pathway dual-hit model, better explaining  
20 ASD risk than the well-accepted mutation burden model.

21 In multiple analyses with independent datasets, hundreds of variants or genes consistently  
22 converge to several canonical pathways. Unlike the reported gene groups or networks,  
23 these pathways define novel, relevant, recurrent and systematic ASD biology. At sub-  
24 pathway level, most variants disrupt the pathway-related gene functions, and multiple  
25 interacting variants spotlight key modules, e.g. cAMP second-messenger system and  
26 mGluR signaling regulation by GRK in synapses. At super-pathway level, these distinct  
27 pathways are highly interconnected, and further converge to a few biology themes, i.e.  
28 synaptic function, morphology and plasticity. Therefore, ASD is a not just multi-genic  
29 but a multi-pathway disease.

30

31

32

## 1 **Introduction**

2 Autism spectrum disorder (ASD) covers a range of complex genetic diseases. Genome  
3 wide molecular profiling is a proven strategy for complex disease studies. Indeed,  
4 thousands of genomic variants or loci have been identified as potential ASD causes<sup>1-12</sup>.  
5 These results confirm the genetic complexity of ASD and provide valuable biological  
6 insights. Yet greater challenge remains: how to turn these enormous datasets into solid  
7 and systematic understanding of the disease mechanism, i.e. biologically relevant  
8 molecular pathways, not just a list of associated genes, their groups or networks? In fact,  
9 this is the common problem remaining for all genome wide studies or complex diseases,  
10 not just ASD.

11 Recently, two whole exome studies under two consortia, the Simons Simplex Collection  
12 (SSC)<sup>10,13</sup> and the Autism Sequencing Consortium (ASC)<sup>11,14</sup>, analyzed thousands of  
13 ASD families or cases-controls producing a vast amount of genetic data. These efforts  
14 identified thousands of rare mutations and firmly established their roles in ASD<sup>15</sup>.  
15 Because these variants rarely recur, major challenges remain as to: 1) evaluate the disease  
16 association of individual variants; 2) pinpoint most driver events from a huge pool of  
17 passengers; 3) replicate independent studies, or 4) verify their results systematically.  
18 Despite the important and inspiring discoveries, a coherent and systematic understanding  
19 of autism biology has not been achieved with these enormous studies<sup>16</sup>.

20 To address these challenges, we devised a novel integrated analysis across multiple levels,  
21 i.e. variant, gene and pathway levels. This multi-level approach has major advantages  
22 over the classical one-level approach. First, it produces more informative, systematic,  
23 holistic genetic understanding. Second, multiple-level/angle screenings of the same data  
24 is more rigorous, reaches more robust conclusions. Third, it provides more sophisticated  
25 and relevant classification and prioritization of *de novo* (DN) mutations and redefines  
26 recurrence across different levels, which makes novel and powerful analyses possible  
27 with rare events.

28 We applied this approach to both SSC<sup>10</sup> and ASC<sup>11</sup> whole exome studies, and identified  
29 hundreds of potential causal mutations. We quantified and identified substantial  
30 consistence both within and between studies, revealing a sequential convergence from  
31 variant, gene to pathway level. We deeply dissected ASD genetic association, and built a  
32 novel and more inclusive gene+pathway dual-hit model which could be generalizable to  
33 CNV or GWAS data. We reconstructed novel, replicable, systematic and multiscale  
34 molecular mechanisms for ASD. They provide solid and actionable molecular roadmaps  
35 for the development of effective and personalized ASD diagnostics and therapeutics.  
36 Note this multi-level integrated analysis is generally useful for other complex diseases,  
37 problems and genomic studies.

## 1 **Sequential convergence from variant, gene to pathway level**

2 For multi-level analysis, we first selected ASD related DN mutations, genes and  
3 pathways in probands or cases in SSC or ASC studies as described in Methods. The  
4 results are listed in Table 1 and Table S4. We applied the same selection procedure to  
5 siblings in SSC for control.

6 ASD mutations from different cohorts do not replicate at variant level, but increasingly  
7 do so at the gene and pathway level (Fig. 1a). At variant level, 0 vs 1 of the 3348 ASC-  
8 selected variants replicate in the 1213 SSC-selected vs 3392 SSC-considered lists (p-  
9 value=0.74). At gene level, 42 vs 60 of the 182 ASC-selected genes are replicated in the  
10 540 SSC-selected vs 1083 SSC-considered lists (p-value= $9.3 \times 10^{-4}$ ). At pathway level, 4  
11 vs 5 of the 5 ASC-selected pathways are replicated in the 9 SSC-selected vs 199 SSC-  
12 considered lists (p-value= $9.7 \times 10^{-6}$ ). Although the background (considered) space  
13 collapses across the 3 levels as expected, the overlap ratio between studies keeps  
14 increasing. Therefore, ASD mutations show multi-level sequential convergence. In  
15 opposite, mutations from probands and siblings in the same SSC cohort do not or rarely  
16 replicate at all 3 levels, and do not converge (Fig. 1b).

17 Besides direct replication, pathway level analysis show extra reproducibility (Fig. 1c-d).  
18 Pathway analysis statistics ( $-\log_{10}$  P-val) are highly correlated between SSC and ASC  
19 ( $R^2=0.570$ ), but not so ( $R^2=0.030$ ) between probands and siblings in SSC.

20 The actual replicability between studies should be even higher given that 1) the genetic  
21 background is much more divergent between different cohorts than between probands  
22 and siblings in the same cohort; 2) the exome-seq assay and raw data processing  
23 procedures differ between the two studies.

24

25 ASD mutations within the same cohort do not recur at variant level, but highly and  
26 increasingly so at gene and pathway level (Fig. S1a). The analysis was done with  
27 available data from SSC<sup>10</sup>. At variant level, 0 of 1213 selected vs 5 of the 3392  
28 considered variants are recurrent (p-value=1.0). At gene level, 107 of 540 selected vs 110  
29 of the 1083 considered genes are recurrent (p-value= $5.0 \times 10^{-31}$ ). At pathway level, 9 of 9  
30 selected vs 22 of the 199 considered pathways are recurrent (p-value= $8.9 \times 10^{-9}$ ). In  
31 opposite, mutations in siblings in the same SSC cohort do not recur or less so at all 3  
32 levels (Fig. S1b).

33 Gene and pathway level analysis show extra evidence of recurrence. As described above,  
34 no variants are recurrent literally, but 240 variants come from recurrent genes in probands.  
35 These gene-level recurrent variants are enriched in both the selected genes and pathways  
36 (Fig. S1c). In selected genes, such recurrent events are 31.9 and 2.53 times enriched vs in  
37 other genes and in siblings (p-val <0.001). In selected pathways, recurrent events are  
38 2.08 and 3.21 times enriched vs outside the pathways and in siblings (p-val <0.001). For

1 siblings, the selected genes but not the selected pathways are enriched for recurrent  
2 variants.

3 The higher-level recurrence and replication between SSC and ASC probands but not for  
4 SSC siblings: 1) indicates that our multi-level approach is both sensitive and selective; 2)  
5 suggests our results are likely true and general.

## 6 **Autism genetic association dissected across multiple levels**

7 In this and following sections, we work with the SSC data only unless noted otherwise.  
8 The study is well controlled with simple data structure<sup>10</sup>, ideal for association and  
9 function analysis. For association analysis, we use all DN variants for testing power. For  
10 pathway and function analysis, we focus on validated variants only (Methods).

11 With no recurrence or annotation, the DN events tell little on ASD genetics at variant  
12 level alone. To fully dissect the ASD genetic association, we take their gene level and  
13 pathway level effects into account. Indeed, variant effects at these two levels largely  
14 determine its association with ASD: 1) whether (and how much) the variant disrupts  
15 genes; 2) whether (and potentially how much) it hits the selected pathways.

16

17 Probands have more variants in general, particularly those disrupt genes and hit selected  
18 pathways. Probands have 55% more LGD or Likely Gene Disrupting (0.175 vs 0.113,  
19  $p=2.1\times 10^{-6}$ ) and 11% more missense variants (0.667 vs 0.601,  $p=2.2\times 10^{-2}$ ) than siblings,  
20 but only 6% more silent variants (0.515 vs 0.484,  $p=7.8\times 10^{-2}$ ) (Fig. S2 row 1). This is  
21 consistent with the original analysis<sup>10</sup>. In addition, they have 39% more variants within  
22 selected pathways, but only 12% more outside (Fig. 2 row 1). In other words, most of the  
23 differences between probands and siblings fall in LGD and missense categories within  
24 selected pathways. This difference is well exhibited by variant distributions in Wnt and  
25 synapse pathways (Fig. S5-7).

26 Proband variants are more (likely, frequently) gene disrupting. As described above,  
27 probands have more events in LGD and missense categories and in general. After  
28 adjusting for the event numbers per pathway assignment or in total (row 2 in Fig. 2 and  
29 Fig. S2), probands still have 78%, 33% and 37% higher LGD within selected pathways,  
30 outside and together ( $p=1.3\times 10^{-2}$ ,  $3.0\times 10^{-4}$  and  $2.8\times 10^{-5}$  respectively). This difference is  
31 well exhibited by in Wnt and synapse pathways (Fig. S5-7). The missense variant ratios  
32 are similar in probands and siblings (row 2 in Fig. 2 and Fig. S2). However, greater  
33 portions of missense variants are gene damaging in probands vs siblings (0.58 vs 0.43  
34 and 0.50 vs 0.47 within and outside selected pathways,  $p<0.05$  and 0.1 respectively) as  
35 predicted by SIFT<sup>17</sup> (Fig. 4a). In addition, more missense variants in selected pathways  
36 hit a functional domain in probands vs siblings (0.747 vs 0.558,  $p\text{-val}<0.05$ ) (Fig. 4b),

1 especially in Wnt and synapse pathways (Fig. S8-9, and more details in Supplementary  
2 Text Section 4).

3 Proband variants are more (likely, frequently) pathway hitting. Probands have higher  
4 absolute event rates than siblings in selected pathways (0.11 vs 0.08,  $p=4.2\times 10^{-4}$ ),  
5 especially in LGD (0.021 vs 0.008,  $p=2.7\times 10^{-4}$ ) and missense (0.053 vs 0.036,  $p=$   
6  $3.5\times 10^{-3}$ ) categories, but not the silent category (0.033 vs 0.032,  $p=0.45$ ). After adjusted  
7 for event numbers within each category or in total, probands still have consistently higher  
8 pathway event rates than siblings for both LGD (0.12 vs 0.07,  $p=4.1\times 10^{-2}$ ) and missense  
9 categories (0.08 vs 0.06,  $p=2.2\times 10^{-2}$ ), but not for the silent category (0.06 vs 0.07,  $p=$   
10 0.60) (row 3 in Fig. 2).

11

12 We proposed a gene+pathway dual-hit (or two-factor) model for ASD genetic association  
13 based on our results above (Fig. 2 column 3): disrupting effect on target genes (G) and  
14 hitting the relevant pathways or not (P). These two factors have significant association  
15 with ASD both marginally and conditionally as described above. In our model, variant  
16 load/burden per person (V) becomes less relevant and marked as hidden. Because the  
17 extra variants mostly fall into the gene disrupting and pathway hitting categories (Fig. 2  
18 row 1, described above).

19 There is also significant interaction between gene and pathway factors (Fig. 2 row 1).  
20 Probands and siblings have the biggest differences in variants that are both gene  
21 disrupting and pathway hitting. The differences diminish outside the pathways or  
22 disappear completely in the silent category. Indeed, this interaction is significant, as  
23 indicated by significant overrepresentation in LGD hitting the pathways in probands (52  
24 occurred vs 34.6 expected events,  $p=0.001$ , Table S1).

25 What we proposed is essentially a Noisy-AND model, i.e. risk genetic variant tend to be  
26 both gene disrupting AND pathway hitting. The model is Noisy because our knowledge  
27 on gene disrupting and pathway assignment is incomplete or penetrance incomplete.

28

29 We also estimate the prevalence of DN events with different gene and pathway level  
30 effects (Fig. S3). These statistics are similar to per patient variant burden stats (Fig. 2 row  
31 1) and consistent with our two-factor genetic model for ASD (Fig. 2 row 1). With the DN  
32 variants alone, this model explains at least 5% (2.8% within and 2.2% outside selected  
33 pathways) of all ASD cases (Fig. S3). Although consistent with the LoF mutation  
34 contribution in the ASC study<sup>11</sup>, this is likely a substantial under-estimation, since not all  
35 variants are called and not all genes in the relevant pathways are known. In addition,  
36 when other types of variants (CNV, common variants or transmitted/inherited variants)  
37 are considered, this model can be generic and more descriptive (more in Supplementary  
38 Text Section 2).

## 1 Pathways of DN events, integrated molecular mechanism

2 Selected by our special pathway-level testing procedure, these pathways form a novel,  
3 coherent yet non-redundant set of ASD disease mechanisms (Table 1). These pathways  
4 are novel in multiple aspects: 1) first time report the target pathway is involved in ASD  
5 (Actin, MAPK, T-junction), 2) there are some evidence in literature, but this is the first  
6 report based on whole exome/genome analysis with statistical significance (Lysine,  
7 GABA, Wnt, Circ, Glut); 3) for all pathways, this is the first report with pathway graphs  
8 on detailed molecular mechanisms for ASD; 4) mostly being causal, they may also  
9 explain associated symptoms of ASD, including intellectual disability<sup>18</sup> (Glut, GABA),  
10 sleeping<sup>19</sup> (Circ) and digestive<sup>20</sup> (digestion) problems.

11 Importantly, the pathway graphs integrate disease variants and genes from multiple  
12 datasets: SSC<sup>10</sup>, ASC<sup>11</sup> or SFARI Gene database<sup>21</sup> (Fig. 4, Fig. S4). These pathways are  
13 likely true and primary molecular mechanism for ASD as they are consistently selected in  
14 these independent analyses. These analyses agree in details too: they frequently converge  
15 to the same genes, gene groups (nodes) or the same signaling branch in a pathway. They  
16 also complement each other. For instance, SSC and ASC data provide numerous novel  
17 ASD associated genes besides those collected in SFARI Gene.

18

19 The pathway list and data integrated pathway graphs provide abundant novel, coherent  
20 and systematic insights on ASD mechanism. We focus on three pathways for example.

21 **1. Wnt signaling pathway: the canonical branch only (Fig. 4a).** All DN events from  
22 SSC and ASC, and all SFARI genes converge to the canonical Wnt pathway. However,  
23 just a few events/genes hit noncanonical Wnt pathways, which are mostly shared by the  
24 canonical branch or other selected pathways.

25 In addition, all aspects or steps of canonical Wnt signaling are involved in ASD (Fig. 4a).  
26 These include Wnt and co-receptor LRP5/6, messenger Dvl, key component of the  
27 destruction complex: APC, GSK3 and CK1 $\epsilon$ , other key players in  $\beta$ -catenin  
28 phosphorylation/ubiquitination/degradation: TBL1 in p53-induced SCF-like complex,  
29 and  $\beta$ -TrCP in Skp1-Cullin-F-box (SCF) E3 ubiquitin ligase complex, PS-1 (Presenilin).  
30 Finally, repressors or activators (chromatin remodelers) in  $\beta$ -catenin directed  
31 transcription, CHD8 (Duplin), RUVBL1 (Pontin52), CREBBP (CBP).

32

33 **2. The whole GABAergic synapse pathway is involved in ASD,** particularly the  
34 following parts (Fig. 4b):

35 1) GABAA receptor or signal in the postsynaptic neurons, and the negative feedback  
36 loops (Gi/o, AC) in pre- and post-synaptic neurons, and the clearance channel through  
37 GABA transporters (GATs) on the presynaptic terminal or neighboring glial cells.

38 2) Glial cells besides the presynaptic and postsynaptic neurons.

1

2 **3. The whole Glutamatergic synapse pathway is involved in ASD**, particularly the  
3 following parts (Fig. 4c):

4 1) ionotropic glutamate receptor (iGluRs, NMDARs) signal, and the postsynaptic density  
5 scaffold proteins (SHANKs etc), the consequent synapse formation and plasticity.

6 2) metabotropic glutamate receptors (mGluRs, mGluR1, 5, 7, 8), the coupled *G* proteins  
7 (Gs, Gi and Go) and the second messenger systems downstream (Ca<sup>2+</sup>, cAMP, DAG,  
8 IP3).

9 3) the inhibitory autoreceptor mechanism that suppresses excess glutamate release in  
10 presynaptic neurons (mGluR7, Gi/o, GRK, AC).

11 4) Glial cells besides the presynaptic and postsynaptic neurons, especially in the  
12 clearance and recycle of glutamate.

13

14 Other pathways and graphs are equally informative, many of them are also supported by  
15 literature (Table 1). For details, please check the Supplementary Text Section 3 and Fig.  
16 S4.

### 17 **Subpathway biology, coherent fine details**

18 We analyzed the functional consequences of DN variants in selected pathways. Here we  
19 focus on missense but not LGD variants. Because the latter are highly destructive on  
20 overall protein structure and function (position insensitive), while the former are subtle  
21 and precisely tell what functions are perturbed in ASD (position sensitive).

22 In probands, missense variants hit the relevant functions or domains in selected pathways.  
23 In Wnt signaling pathway, missense hit the histone acetylation domain KAT11 twice in  
24 CREBBP (CBP) gene and TIP49 domain in RUVBL1, the scaffolding domain WD40 in  
25 TBL1XR1, and the CTNNB1 binding domain in TCF7L1 (Fig. S8). In synapse pathways,  
26 the most essential players, i.e. neurotransmitter receptors, transporters and ion channels  
27 on cell membrane, are heavily targeted (Fig. 4c-d, Fig. S6-7). Missense variants hit the  
28 neurotransmitter glutamate binding domain in GRIN2B (NMDAR) gene, the 7  
29 transmembrane region of GRM7 (mGluR7), and the ion-channel domains in GABRA1  
30 and CACNA1C, the Sodium:neurotransmitter symporter domain in SLC6A1 (GAT) and  
31 SLC6A13 (GAT2/3), among others.

32 In opposite, missense variants in siblings often hit the non-functional regions or the less  
33 relevant regions or genes (Fig. S8-10). This probands-sibling difference is significant  
34 overall (Fig. 4b) and extremely so in the example pathways (Fig. S8-9 and  
35 Supplementary Text Section 4).

36 Autistic missense events on the same genes tend to hit residues extremely close and in the  
37 same domain. This occurs to all cases we observed in Wnt and synapse pathways (Fig.

1 4c-d or Fig. S8-9: ADCY5, CREBBP, SLC6A1 and SLC6A13). These data strongly  
2 suggest that missense events do not occurred in random, but precisely and consistently  
3 targeting specific risky loci for ASD ( $p= 0.002-0.03$ , Supplementary Text Section 4).

4  
5 We identified subpathway clusters of missense events in probands. Each event cluster  
6 hits multiple interacting genes along the pathway. They reveal novel and critical  
7 molecular modules in ASD biology.

8 One cluster hit the cAMP second-messenger system<sup>22</sup> in the Glutamatergic synapse  
9 pathway (Fig. 4d, Fig. S7). Two types of G proteins bind and control Adenylate cyclase  
10 (AC), Gs activates while Gi/o (Gi/Go) inhibits it (green dashed box in Fig. S7). As shown  
11 in Fig. 4d, the G-alpha domains of GNAS (Gs) and GNAO1 (Gi/o) are similar and align  
12 seamlessly in 3D<sup>23</sup>. They compete to bind to AC C2A domain the same way. Missense  
13 variants in these two genes both hit the G-alpha domain, which affect their binding to AC  
14 hence AC's catalytic activity on cAMP production and downstream signal. In parallel,  
15 the two missense events on AC (ADCY5) hit its C1A domain, which perturb AC's  
16 catalytic function too (Fig. 4d). In the direct upstream (Fig. S7), GRM5 (mGluR5) was  
17 hit by a destructive in frame deletion (K679) (Table S5). GRM7 (mGluR7) was hit by a  
18 missense at the 7 transmembrane region (Fig. 4c), which likely render it a strong  
19 antagonist of the transmembrane signal as an unbounded cytosol form.

20 In another cluster, GRK inhibits mGluR signaling by sequestering heterotrimeric G  
21 proteins. See Supplementary Text Section 4 and Fig. S11 for details.

22 All these subpathway level biological stories we present above reveals coherent fine  
23 details on ASD mechanism. This is consistent with yet complement to the integrated  
24 pathway graphs (Fig. 3 and Fig. S6-7).

## 25 **Superpathway biology, emergent big picture**

26 The selected pathways are distinct yet highly interconnected. For example, MAPK feed  
27 into canonical Wnt pathway and inhibit TCF/LEF dependent transcription (Fig. 3a and  
28 Fig. S4c). In addition, they also share numerous other connections. For example, Wnt and  
29 MAPK are both involved in adherens junctions and focal adhesion (Fig. S4g-4h). These  
30 commonly connected pathways are also perturbed in ASD except marginally significant  
31 ( $p.val=0.01-0.10$ , Table S2).

32 Two distinct biological themes or modules emerge from the selected and connected  
33 pathways (Fig. 5). Module I includes Wnt signaling, cell adhesion, junction, and  
34 cytoskeleton etc. They are involved in synapses morphology, i.e. synapse assembly and  
35 stability. Module II includes Glutamatergic synapse, GABAergic synapse, and related  
36 processes. They are involved in synapses functions, i.e. chemical and electrical signals  
37 transmission, regulations and patterns. Module 1 concerns neuronal wiring or the

1 hardware, while module II concerns synaptic transmission or the software. These  
2 modules are distinct in topology too. Connections are dense within each module but none  
3 between them. MAPK pathway is the only bridge node and highly connected in both  
4 modules. There is 1 less prominent theme: transcription (not shown in Fig. 5). Both Wnt  
5 and MAPK pathways end at target gene transcription, which involves chromatin  
6 modification, especially histone lysine methylation branch of Lysine degradation (Table  
7 1). We also did a parallel GO term analysis, which converges to the same set of  
8 biological themes (Supplementary text section 5 and Fig. S12).

9 All mutated pathways or functions converge to synapse biology. Either synaptic function,  
10 morphology or plasticity (as indicated by transcription<sup>24,25</sup>) is disrupted in these cases.  
11 Therefore, ASD is a multi-pathway disease not just multi-genic, and ultimately a synapse  
12 disease.

### 13 **Discussion**

14 We conduct an integrated analysis on ASD exome mutations across multiple levels.  
15 These isolated and rarely occurred events are actually connected and recurrent at higher  
16 (gene and pathway) levels (Fig. 1). In the meantime, the otherwise random and divergent  
17 results become reproducible between independent studies. This cross-validation not only  
18 confirms our results but also justifies our multi-level analysis approach. This novel  
19 approach is equally applicable to other complex diseases.

20  
21 We also did a multi-level association analysis, and proposed a gene+pathway dual-hit  
22 model for ASD risk (Fig. 2). The disease variants need to both: 1) disrupt the target genes;  
23 and 2) hit the relevant pathways. Variants missing either factor become no or less risky,  
24 including the silent variants in the selected pathways or variants outside the pathways. In  
25 this model, contribution of variant load/burden can be explained away hence becomes  
26 less relevant. This model likely applies to other types of genetic variants including CNV  
27 and SNP. Although this is just a descriptive model, with relevant data, it can turn into a  
28 predictive model.

29  
30 We reconstruct a set of coherent and systematic molecular mechanisms for ASD (Fig. 3-5,  
31 Table 1). Importantly, we discover whole pathways or molecular systems that cause the  
32 disease, as supported by multiple independent datasets. These disease pathways not just  
33 present a catalog of ASD genetic associations (Table S5), but further connect hundreds of  
34 interacting genes and variants into a whole, dynamic multiscale system (Fig. 3-5). They  
35 reveal concrete biological mechanism, much more definitive and informative than gene  
36 networks or GO groups in literature. These results greatly advance our understanding on

- 1 ASD, and provide solid guidance for the development of effective diagnosis and
- 2 therapeutics on ASD.

## 1 **Methods**

### 2 *Data collection and integration*

3 The exome-seq DN variants from the SSC cohort<sup>10</sup> and ASC cohort<sup>11</sup> were used for this  
4 study. Please see the original publications for details of the experimental design, quality  
5 control and raw data processing. The final SSC data include 2,517 families, with 2,508  
6 affected children, 1,911 unaffected siblings and the parents of each family. The ASC  
7 data we used consists two cohorts: one includes 1,445 trios, another includes 1601 cases  
8 and 5397 ancestry-matched controls. The ASC paper originally included 825 trios from  
9 the SSC cohort. This overlap was intentionally excluded to create two completely  
10 independent datasets for downstream analysis and comparison.

### 11 *Variant level analysis*

12 Variants were divided into 3 major categories based on their effects on the target genes.  
13 Silent group includes all synonymous variants and those fall in the 3'UTR, 5'UTR,  
14 intergenic, intron, and non-coding regions; Missense group include missense variants;  
15 LGD (likely gene disrupting) or LoF (lose of function) group includes exon indels (both  
16 frame-shift and no-frame-shift), nonsense, and splice-site variants. Variants are selected  
17 for gene and pathway level analyses based on a few criteria: 1) LGD (or LoF) and  
18 missense only, as silent variants are usually not damaging, and have little disease  
19 association as a group (Fig. 2); 2) For SSC study<sup>10</sup>, we only consider validated variants,  
20 which included those experimentally verified or cross-validated or called in at least 2 of  
21 the 3 laboratories (CSHL, Yale or UW). 3) For ASC study<sup>11</sup>, we only consider DN  
22 variants in the trio families or those from the case-control cohorts.

### 23 *Gene level analysis*

24 Selected variants are mapped to target genes. We select genes using the following scoring  
25 function which essentially sums up the weighted evidence for each gene.

26

$$s_i = \sum_j I_{ij} \cdot w_j$$
$$G_i: s_i \geq s_0$$

27 *i*: gene index, *j*: patient index, *I*, indicator on whether a selected variant occurs to the  
28 gene-patient pair, *w*, weight, *s*: score

29 Due to different study designs and data quality, we used slightly different criteria for the  
30 two cohorts. In SSC, we take  $w_j=1/n_j$  (number of selected variants occurred to patient *i*)  
31 and  $s_0=0.5$ , while in ASC  $w_j=1$  and  $s_0=2$ .

1 *Pathway level analysis*

2 We selected pathways enriched for the selected genes. We test for both marginal and  
3 conditional overrepresentation given the previously selected pathways. This procedure  
4 ensures that pathways selected are drivers instead of passengers, which share genes with  
5 the former.

6

7 The analysis is an application of the set theory.

8  $G = \{\text{selected genes above}\}$

9  $P_i = \{\text{pathway or gene set under testing}\}$

10  $P_s = \{\text{selected pathways or gene sets}\}$

11  $P_o = \{\text{all pathways or gene sets}\}$

12  $U = |G \cap P_o|$

13  $V = |G \cap P_o \setminus P_s|$

14  $X = |G \cap P_i|$

15  $Y = |G \cap P_i \setminus P_s|$

16

17 For marginal significance test:

18  $X = j \sim \text{hyperG}(j; |P_o|, |P_i|, U)$

19  $P(X \geq j) = \sum_l \text{PhyperG}(j; |P_o|, |P_i|, U)$ , where  $l = \{j, j+1, \dots, |P_o|\}$

20

21 For conditional significance test:

22  $X = k | P_s \sim Y = k \sim \text{hyperG}(k; |P_o \setminus P_s|, |P_i \setminus P_s|, V)$

23  $P(X \geq k | P_s) = P(Y \geq k) = \sum_l \text{PhyperG}(k; |P_o \setminus P_s|, |P_i \setminus P_s|, V)$ , where  $l = \{k, k+1, \dots, |P_o|\}$

24

25 Here hyperG is the hypergeometric distribution, and PhyperG is the standard probability  
26 mass function of the hypergeometric distribution.

27 The same analysis procedure was applied to KEGG pathways and GO terms. The  
28 metabolic and signaling pathways from KEGG were tested and analyzed together, and  
29 the three branches of GO, i.e. biological process (BP), cellular component (CC),  
30 molecular function (MF) were analyzed separately. We did multiple-testing correction on  
31 P-values using false discovery rate (FDR or q-value).

32 *Variant association*

33 ASD DN variants can be divided into groups based on their gene-level and pathway-level  
34 effects. At gene-level, they are assigned to silent, LGD, missense or nonsilent (LGD +

1 missense) groups, as described above. At pathway level, they either belong to the  
2 Selected pathways or Others.

3 The ASD association of these variant groups can be measured by rate difference (over  
4 noise), rate ratio ( $\theta$ ) or  $\log \theta$  between probands and siblings. To test the rate difference  
5 between probands and siblings, we conducted two proportion z-test for conditional rates,  
6 and two sample t-test for marginal rates. Odd ratio tests gave similar results as in our  
7 conditional rate tests, but is not suitable for marginal tests on absolute variant rates.

### 8 *Pathway data integration and visualization*

9 Pathview package<sup>26</sup> was used for pathway based data integration and visualization.  
10 Variants were first mapped to the target genes, which are then mapped and visualized  
11 onto the selected KEGG pathway graphs. In disease gene view (Fig. 3, Fig. S4), variant  
12 targeted genes from SSC and ASC, and SFARI genes are collected, integrated and shown  
13 in the relevant pathways. Different data sources were marked by colors, gene level scores  
14 by brightness, and corresponding pathway analysis p-values are also shown. In variant  
15 type views (Fig. S5-7), DN variants from SSC are project and visualized on the target  
16 pathways. Variant types or effects (LGD, missense, or silent) are marked by different  
17 colors, their corresponding event counts are also shown.

### 18 *Protein structure and function analysis*

19 Exome variants were mapped to amino acid changes in the target protein using  
20 Bioconductor VariantAnnotation package<sup>27</sup>. 1D Linear protein domain structures were  
21 visualized using cBioPortal Mutationmapper<sup>28</sup>. Protein domain data were retrieved from  
22 Pfam database<sup>29</sup>, and provide updated the protein domain locations. 3D protein structure  
23 data were retrieved from the Protein Data Bank (PDB)<sup>30</sup>. The mapped exome variants  
24 coded into amino acid changes were then visualized with the 3D protein structure using  
25 Pymol ([www.pymol.org](http://www.pymol.org)).

26

## 27 **References**

- 28 1 O'Roak, B. J. *et al.* Exome sequencing in sporadic autism spectrum disorders identifies severe de  
29 novo mutations. *Nat. Genet.* **43**, 585-589, doi:10.1038/ng.835 (2011).
- 30 2 Neale, B. M. *et al.* Patterns and rates of exonic de novo mutations in autism spectrum disorders.  
31 *Nature* **485**, 242-245, doi:10.1038/nature11011 (2012).
- 32 3 O'Roak, B. J. *et al.* Sporadic autism exomes reveal a highly interconnected protein network of de  
33 novo mutations. *Nature* **485**, 246-250, doi:10.1038/nature10989 (2012).
- 34 4 Sanders, S. J. *et al.* De novo mutations revealed by whole-exome sequencing are strongly  
35 associated with autism. *Nature* **485**, 237-241, doi:10.1038/nature10945 (2012).
- 36 5 Iossifov, I. *et al.* De novo gene disruptions in children on the autistic spectrum. *Neuron* **74**, 285-  
37 299, doi:10.1016/j.neuron.2012.04.009 (2012).

- 1 6 Michaelson, J. J. *et al.* Whole-genome sequencing in autism identifies hot spots for de novo  
2 germline mutation. *Cell* **151**, 1431-1442, doi:10.1016/j.cell.2012.11.019 (2012).
- 3 7 Yu, T. W. *et al.* Using whole-exome sequencing to identify inherited causes of autism. *Neuron* **77**,  
4 259-273, doi:10.1016/j.neuron.2012.11.002 (2013).
- 5 8 Jiang, Y. H. *et al.* Detection of clinically relevant genetic variants in autism spectrum disorder by  
6 whole-genome sequencing. *Am. J. Hum. Genet.* **93**, 249-263, doi:10.1016/j.ajhg.2013.06.012  
7 (2013).
- 8 9 Parikshak, N. N. *et al.* Integrative functional genomic analyses implicate specific molecular  
9 pathways and circuits in autism. *Cell* **155**, 1008-1021, doi:10.1016/j.cell.2013.10.031 (2013).
- 10 10 Iossifov, I. *et al.* The contribution of de novo coding mutations to autism spectrum disorder.  
11 *Nature* **515**, 216-221, doi:10.1038/nature13908 (2014).
- 12 11 De Rubeis, S. *et al.* Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature* **515**,  
13 209-215, doi:10.1038/nature13772 (2014).
- 14 12 Yuen, R. K. *et al.* Whole-genome sequencing of quartet families with autism spectrum disorder.  
15 *Nat. Med.* **21**, 185-191, doi:10.1038/nm.3792 (2015).
- 16 13 Fischbach, G. D. & Lord, C. The Simons Simplex Collection: a resource for identification of  
17 autism genetic risk factors. *Neuron* **68**, 192-195, doi:10.1016/j.neuron.2010.10.006 (2010).
- 18 14 Buxbaum, J. D. *et al.* The autism sequencing consortium: large-scale, high-throughput sequencing  
19 in autism spectrum disorders. *Neuron* **76**, 1052-1056, doi:10.1016/j.neuron.2012.12.008 (2012).
- 20 15 Ronemus, M., Iossifov, I., Levy, D. & Wigler, M. The role of de novo mutations in the genetics of  
21 autism spectrum disorders. *Nat Rev Genet* **15**, 133-141, doi:10.1038/nrg3585 (2014).
- 22 16 Willsey, A. J. & State, M. W. Autism spectrum disorders: from genes to neurobiology. *Curr. Opin.*  
23 *Neurobiol.* **30**, 92-99, doi:10.1016/j.conb.2014.10.015 (2015).
- 24 17 Ng, P. C. & Henikoff, S. SIFT: Predicting amino acid changes that affect protein function. *Nucleic*  
25 *Acids Res.* **31**, 3812-3814 (2003).
- 26 18 Zoghbi, H. Y. & Bear, M. F. Synaptic dysfunction in neurodevelopmental disorders associated  
27 with autism and intellectual disabilities. *Cold Spring Harb Perspect Biol* **4**,  
28 doi:10.1101/cshperspect.a009886 (2012).
- 29 19 Glickman, G. Circadian rhythms and sleep in children with autism. *Neurosci. Biobehav. Rev.* **34**,  
30 755-768, doi:10.1016/j.neubiorev.2009.11.017 (2010).
- 31 20 Horvath, K., Papadimitriou, J. C., Rabsztyrn, A., Drachenberg, C. & Tildon, J. T. Gastrointestinal  
32 abnormalities in children with autistic disorder. *The Journal of pediatrics* **135**, 559-563 (1999).
- 33 21 Abrahams, B. S. *et al.* SFARI Gene 2.0: a community-driven knowledgebase for the autism  
34 spectrum disorders (ASDs). *Mol Autism* **4**, 36, doi:10.1186/2040-2392-4-36 (2013).
- 35 22 Salin, P. A., Malenka, R. C. & Nicoll, R. A. Cyclic AMP mediates a presynaptic form of LTP at  
36 cerebellar parallel fiber synapses. *Neuron* **16**, 797-803 (1996).
- 37 23 Tesmer, J. J., Sunahara, R. K., Gilman, A. G. & Sprang, S. R. Crystal structure of the catalytic  
38 domains of adenylyl cyclase in a complex with G $\alpha$ .GTP $\gamma$ S. *Science* **278**, 1907-1916  
39 (1997).
- 40 24 Alberini, C. M. Transcription factors in long-term memory and synaptic plasticity. *Physiol. Rev.*  
41 **89**, 121-145, doi:10.1152/physrev.00017.2008 (2009).
- 42 25 Cortes-Mendoza, J., Diaz de Leon-Guerrero, S., Pedraza-Alva, G. & Perez-Martinez, L. Shaping  
43 synaptic plasticity: the role of activity-mediated epigenetic regulation on gene transcription.  
44 *International journal of developmental neuroscience : the official journal of the International*  
45 *Society for Developmental Neuroscience* **31**, 359-369, doi:10.1016/j.ijdevneu.2013.04.003 (2013).
- 46 26 Luo, W. & Brouwer, C. Pathview: an R/Bioconductor package for pathway-based data integration  
47 and visualization. *Bioinformatics* **29**, 1830-1831, doi:10.1093/bioinformatics/btt285 (2013).
- 48 27 Obenchain, V. *et al.* VariantAnnotation: a Bioconductor package for exploration and annotation of  
49 genetic variants. *Bioinformatics* **30**, 2076-2078, doi:10.1093/bioinformatics/btu168 (2014).
- 50 28 Gao, J. *et al.* Integrative analysis of complex cancer genomics and clinical profiles using the  
51 cBioPortal. *Sci Signal* **6**, p11, doi:10.1126/scisignal.2004088 (2013).
- 52 29 Finn, R. D. *et al.* Pfam: the protein families database. *Nucleic Acids Res.* **42**, D222-230,  
53 doi:10.1093/nar/gkt1223 (2014).
- 54 30 Rose, P. W. *et al.* The RCSB Protein Data Bank: new resources for research and education.  
55 *Nucleic Acids Res.* **41**, D475-482, doi:10.1093/nar/gks1200 (2013).
- 56




SSC Pathways	p.val	q.val	p.con	q.con	<i>j</i>	<i>k</i>	Reference
hsa00310 Lysine degradation	$8.0 \times 10^{-05}$	0.02	$8.0 \times 10^{-05}$	0.02	8	8	<sup>1,2</sup>
hsa04727 GABAergic synapse	$4.9 \times 10^{-03}$	0.31	$3.9 \times 10^{-03}$	0.03	8	8	<sup>3,4</sup>
hsa04974 Protein digestion and absorption	$1.5 \times 10^{-02}$	0.35	$9.7 \times 10^{-03}$	0.07	7	7	<sup>5</sup>
hsa04310 Wnt signaling pathway	$7.9 \times 10^{-03}$	0.31	$8.5 \times 10^{-03}$	0.08	10	9	<sup>6,7</sup>
hsa04810 Regulation of actin cytoskeleton	$2.5 \times 10^{-02}$	0.35	$6.3 \times 10^{-03}$	0.06	12	12	<sup>8,9</sup>
hsa04010 MAPK signaling pathway	$2.1 \times 10^{-02}$	0.35	$9.1 \times 10^{-03}$	0.07	14	10	<sup>10,11</sup>
hsa04530 Tight junction	$1.7 \times 10^{-02}$	0.35	$6.6 \times 10^{-02}$	0.17	9	5	<sup>12,13</sup>
hsa04713 Circadian entrainment	$7.7 \times 10^{-03}$	0.31	$6.6 \times 10^{-02}$	0.14	8	3	<sup>14,15</sup>
hsa04724 Glutamatergic synapse	$2.1 \times 10^{-02}$	0.35	$1.9 \times 10^{-01}$	0.19	8	2	<sup>16,17</sup>

ASC Pathways	p.val	q.val	p.con	q.con	<i>j</i>	<i>k</i>	Reference
hsa00310 Lysine degradation	$6.2 \times 10^{-05}$	0.01	$6.2 \times 10^{-05}$	0.01	5	5	<sup>1,2</sup>
hsa04713 Circadian entrainment	$1.5 \times 10^{-03}$	0.15	$9.9 \times 10^{-04}$	0.01	5	5	<sup>14,15</sup>
hsa04976 Bile secretion	$3.5 \times 10^{-03}$	0.18	$8.4 \times 10^{-03}$	0.06	4	3	<sup>5</sup>
hsa04727 GABAergic synapse	$7.8 \times 10^{-03}$	0.21	$4.4 \times 10^{-02}$	0.12	4	2	<sup>3,4</sup>
hsa04010 MAPK signaling pathway	$7.1 \times 10^{-03}$	0.21	$6.7 \times 10^{-02}$	0.07	7	4	<sup>10,11</sup>


**Table 1. Significant pathways selected from SSC and ASC exome data.** Columns *j* and *k* are the marginal and conditional counts of selected genes. These pathways are likely drivers or disease causing pathways due to the special analysis procedure (Methods). See Table S4 for full lists of selected variants and genes.

## References


- 1 Akbarian, S. & Huang, H. S. Epigenetic regulation in human brain-focus on histone lysine methylation. *Biol. Psychiatry* **65**, 198-203, doi:10.1016/j.biopsych.2008.08.015 (2009).
- 2 De Rubeis, S. *et al.* Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature* **515**, 209-215, doi:10.1038/nature13772 (2014).
- 3 Coghlan, S. *et al.* GABA system dysfunction in autism and related disorders: from synapse to symptoms. *Neurosci. Biobehav. Rev.* **36**, 2044-2055, doi:10.1016/j.neubiorev.2012.07.005 (2012).
- 4 Chao, H. T. *et al.* Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. *Nature* **468**, 263-269, doi:10.1038/nature09582 (2010).
- 5 Horvath, K., Papadimitriou, J. C., Rabsztyrn, A., Drachenberg, C. & Tildon, J. T. Gastrointestinal abnormalities in children with autistic disorder. *The Journal of pediatrics* **135**, 559-563 (1999).
- 6 Kalkman, H. O. A review of the evidence for the canonical Wnt pathway in autism spectrum disorders. *Mol Autism* **3**, 10, doi:10.1186/2040-2392-3-10 (2012).
- 7 Okerlund, N. D. & Cheyette, B. N. Synaptic Wnt signaling-a contributor to major psychiatric disorders? *J Neurodev Disord* **3**, 162-174, doi:10.1007/s11689-011-9083-6 (2011).
- 8 Pinto, D. *et al.* Functional impact of global rare copy number variation in autism spectrum disorders. *Nature* **466**, 368-372, doi:10.1038/nature09146 (2010).
- 9 Luo, L. Actin cytoskeleton regulation in neuronal morphogenesis and structural plasticity. *Annu. Rev. Cell Dev. Biol.* **18**, 601-635, doi:10.1146/annurev.cellbio.18.031802.150501 (2002).
- 10 Giachello, C. N. *et al.* MAPK/Erk-dependent phosphorylation of synapsin mediates formation of functional synapses and short-term homosynaptic plasticity. *J. Cell Sci.* **123**, 881-893, doi:10.1242/jcs.056846 (2010).
- 11 Thomas, G. M. & Huganir, R. L. MAPK cascade signalling and synaptic plasticity. *Nat Rev Neurosci* **5**, 173-183, doi:10.1038/nrn1346 (2004).
- 12 Liu, Z., Li, N. & Neu, J. Tight junctions, leaky intestines, and pediatric diseases. *Acta Paediatr.* **94**, 386-393 (2005).
- 13 Tang, V. W. Proteomic and bioinformatic analysis of epithelial tight junction reveals an unexpected cluster of synaptic molecules. *Biol Direct* **1**, 37, doi:10.1186/1745-6150-1-37 (2006).
- 14 Glickman, G. Circadian rhythms and sleep in children with autism. *Neurosci. Biobehav. Rev.* **34**, 755-768, doi:10.1016/j.neubiorev.2009.11.017 (2010).
- 15 Bourgeron, T. The possible interplay of synaptic and clock genes in autism spectrum disorders. *Cold Spring Harb. Symp. Quant. Biol.* **72**, 645-654, doi:10.1101/sqb.2007.72.020 (2007).
- 16 Delorme, R. *et al.* Progress toward treatments for synaptic defects in autism. *Nat. Med.* **19**, 685-694, doi:10.1038/nm.3193 (2013).
- 17 Cusco, I. *et al.* Autism-specific copy number variants further implicate the phosphatidylinositol signaling pathway and the glutamatergic synapse in the etiology of the disorder. *Hum. Mol. Genet.* **18**, 1795-1804, doi:10.1093/hmg/ddp092 (2009).



**Figure 1 Multi-level comparison of DN mutations between or within ASD whole exome studies.** Venn diagrams and test statistics on overlap a) between SSC and ASC ASD cohorts, and b) between probands and siblings of SSC, at different levels. Correlation of pathway analysis statistics c) between SSC and ASC ASD cohorts, and d) between probands and siblings of SSC. Term “considered” or “selected” refers to items before or after selection process at each level (Methods). See Table S4 for full lists of selected variants and genes used in the analysis.




**Figure 2. Autism genetic association analysis across variant, gene and pathway levels with the SSC exome mutation data.** Column 1 and 2: DN event rates and association test by gene and pathway level effects; column 3: A descriptive model for autism genetic association. Rows are marginal (Row 1) and conditional (Row 2-3) association tests and statistics, and corresponding model representations. Variants are grouped based on gene-level effects (G): Silent, Missense, LGD and Nonsilent (Missense + LGD) (details in Methods), and pathway level effects (P): hitting Selected pathways or Others. The associations marked in column 3 should be taken as the theme for corresponding row. Notation  $\alpha(G; A)$  and  $\alpha(G; A | P)$  are read as marginal association between G and A, and their conditional association given P. The association can be measured by rate difference (over noise), rate ratio ( $\theta$ ) or log  $\theta$ . P-values comes from the rate difference tests. Error bars represent standard error of the mean (SEM).




**Figure 3** An integrated view of autism associated DN variants or genes from multiple sources in selected KEGG pathways: a) hsa04310 Wnt signaling pathway, b) hsa04727 GABAergic synapse, and c) hsa04724 Glutamatergic synapse (next page). DN variants data come from SSC and ASC studies, and reported autism

genes from SFARI Gene Database. Gene level scores (Methods) are marked by color. P-values are from pathway analysis (Table 1). Data are integrated and visualized on KEGG pathway graphs using Pathview (23).



**Figure 3. An integrated view of autism associated DN variants or genes from multiple sources in selected KEGG pathways: c) hsa04724 Glutamatergic synapse (continued).**



**Figure 4. Functional consequences of autism associated missense mutations.** a) ratios of damaging events as predicted by SIFT; b) ratios of events hitting a function domain defined in Pfam; c) 1D protein domain structure and missense variants of all neurotransmitter receptors, transporters and ion channel genes in synapse pathways (the bold black box nodes in pathway graphs in Figure S6-7); d) 1 and 3D protein structures and missense variants hitting the Adenylate cyclase (AC), i.e. ADCY5, and interacting G proteins, GNAS (Gs) and GNAO1 (Gi/o). The pathway context is shown in the green dashed box in in Supplementary Fig. 7. AC controls the production of cAMP second-messenger in synapse (Supplementary Text Section 4). Error bars represent standard error of the mean (SEM).

